Clinical pharmacokinetics of albendazole in children with neurocysticercosis

American Journal of Therapeutics

Volumn 4, Issue 1, 1997, Pages 23-26

  Jung, Helgi ^a,b,d   Sánchez, Mónica ^a   González Astiazarán, Adalberto ^c   Martínez, José M ^c   Suástegui, Roberto ^c   González Esquivel, Dinora F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d Laboratorio de Neuropsicofarmacología   (Mexico)

Author keywords

albendazole; brain cysticercosis; children; pharmacokinetics

Indexed keywords

ALBENDAZOLE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROCYSTICERCOSIS; PEDIATRICS; PRIORITY JOURNAL;

EID: 0030979089     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199701000-00005     Document Type: Article

References (18)

1. Kalra V, Sethi A: Childhood neurocysticercosis - epidemiology, diagnosis and course. Acta Paediatr Jpn 1992;34:365-70.
2. López-Hernández A, Garaizar C: Childhood cerebral cysticercosis: Clinical features and computed tomographic findings in 89 mexican children. Can J Neurol Sci 1982;9:401-407.
3. Sotelo J, Escobedo F, Penagos P: Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol 1988;45:532-534.
4. Sotelo J, Del Brutto OH, Penagos P, et al.: Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72.
5. Overbosch D: Neurocysticercosis. Schweiz Med Wochenschr 1992;122:893-898.
6. Hurtado M, Medina MT, Sotelo J, Jung H: Sensitive high performance liquid chromatographic assay for albendazole and its main metabolite albendazole sulphoxide in plasma and cerebrospinal fluid. J Chromatogr 1989;494: 403-407.
7. Metzler C: Nonlin: A Computer Program for Parameter Estimation in Nonlinear Situations, Upjohn, Kalamazoo, 1969.
8. Yamaoka K, Nakagawa T, Uno T: Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6: 547-558.
9. Marriner SE, Morris DL, Dickson B, Bogan JA: Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705-708.
10. Cotting J, Zeugin T, Steiger U, Reichen J: Albendazole kinetics in patients with echinococcosis: Delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 1990;38:605-608.
11. Delatour P, Benoit E, Besse S, Boukraa A: Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica 1991;21:217-221.
12. Penicaut B, Maugein P, Maisonneuve H, Rossignol J: Pharmacocinétique et métabolisme urinaire de l'albendazole chez l'homme. Bull Soc Path Ex 1983;76:698-708.
13. Lange H, Eggers R, Bircher J: Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988;34:315-317.
14. Takayanagui O, Jardim E: Therapy for neurocysticercosis. Arch Neurol 1992;49:290-294.
15. Del Brutto OH, Sotelo J, Roman GC: Therapy for neurocysticercosis: A reappraisal. Clin Infect Dis 1993;17:730-735.
16. Jung H, Hurtado M, Sánchez M, Medina MT, Sotelo J: Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 1992;32:28-31.
17. Jung H, Hurtado M, Sánchez M, Medina MT, Sotelo J: Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neurophamacol 1990;13:559-564.
18. Rowland M, Tozer T: Age and Weight. In Clinical Pharmacokinetic, (Eds. Rowland M, Tozer T), Lea & Febiger, Philadelphia, 1989, pp 222-237.